304889-45-0Relevant articles and documents
Synthesis and preliminary biological evaluation of new heterocyclic carboxamide models
Sweidan, Kamal,Engelmann, J?rn,Rayyan, Walid Abu,Sabbah, Dima,Zarga, Musa Abu,Al-Qirim, Tariq,Al-Hiari, Yusuf,Sheikha, Ghassan Abu,Shattat, Ghassan
, p. 417 - 429 (2015/06/22)
The heterocyclic system is a promising core nucleus in many bioactive compounds. This work describes our effort to synthesize and characterize a set of new biphenyl, benzofuran and benzothiophene carboxamide derivatives. Our biological studies showed that
In vivo antihyperlipidemic activity of a new series of N-(Benzoylphenyl) and N-(Acetylphenyl)-1-benzofuran-2-carboxamides in rats
Al-Qirim, Tariq,Shattat, Ghassan,Sweidan, Kamal,El-Huneidi, Waseem,Sheikha, Ghassan Abu,Khalaf, Reema Abu,Hikmat, Suhair
experimental part, p. 401 - 406 (2012/08/13)
A new series of N-(benzoylphenyl) and N-(acetylphenyl)-1-benzofuran-2- carboxamides (3a-3d and 4a'-4c') were synthesized. Compounds (3a, 3b, and 4a'-4c') were tested in vivo using Triton-WR-1339-induced hyperlipidemic rats as an experimental model for their hypolipidemic activity. The tested animals were divided into eight groups: control, hyperlipidemic, 3a, 3b, 4a', 4b', 4c', and bezafibrate. At a dose of 15 mg/kg, the elevated plasma triglyceride (TG) levels were significantly reduced in compounds 3b (p 0.0001) and 4c' (p 0.05) after 12 and 24 h compared to the normal control group. Furthermore, high-density lipoprotein-cholesterol levels were remarkably increased in compounds 3b (p 0.001) and 4c' (p 0.05). Meanwhile, compound 4b' slightly reduced the TG levels after 12 and 24 h. The present study demonstrated new properties of the novel series of benzofuran-2-carboxamides 3b and 4c' as potent lipid-lowering agents. It is, therefore, reasonable to assume that compounds 3b and 4c' may have a promising potential in the treatment of hyperlipidemia and coronary heart diseases. A new series of N-(benzoylphenyl) and N-(acetylphenyl)-1-benzofuran-2-carboxamides (3a-3d and 4a'-4c') were synthesized and most of them were tested in vivo for their hypolipidemic activity. Compounds 3b and 4c' turned out to be potent lipid-lowering agents and thus may have a promising potential in the treatment of hyperlipidemia and coronary heart diseases. Copyright